New: NCI-funded clinical trial search
Mednet Logo
CommunityHematology

Is there a risk of increased side effects with combined radiation and ibrutinib therapy?

Would you change your radiation therapy treatment dose or volume if you needed to treat a chloroma? If a patient had a separate cancer (e.g., skin cancer, breast cancer, etc.), would you recommend stopping Imbruvica or trying to avoid RT?
Community PollStarted

What is your approach to patients on BTKi undergoing radiation?

65 physicians have voted

Join Mednetto vote and see how they answered.

5 Answers
Mednet MemberInvited Expert
Radiation Oncology · Duke University Medical Center
Answered on

It is increasingly common to see patients with various hematologic malignancies requiring palliative RT who are on small molecular inhibitors (such as ibrutinib) or other novel agents. There is often a dearth of information in the medical literature regarding the safety of combining RT with these drugs. In general, unless there is reasonable information confirming the safety of concurrent therapy, when I am treating an area with sensitive normal tissues in the RT field (e.g., bowel, esophagus, oral mucosa, etc.), I will hold the agent while the RT is being administered. For most clinical circumstances, this is a mere 1-2 weeks. If I am treating an area of the body without critical normal tissues (e.g., painful myelomateous lesion in the fem...

Join for free or sign in to see the full answer

Mednet MemberInvited Expert
Hematology · Rutgers Cancer Institute/Rutgers Robert Wood Johnson Medical School
Answered on

This is a great question and comes up frequently in clinical practice, as patients with CLL are at a higher risk for secondary primary malignancies (SPM). Ibrutinib (or other targeted agents) has not been shown to be a radiosensitizer, so it would be safe to continue ibrutinib while receiving radiotherapy (Kosydar et al., Journal of Clinical Oncology 2023). Given the area that is being radiated, I would recommend close follow-up and communication with radiation oncology to ensure there are no issues with bleeding in the area, which ibrutinib could put the patient at a higher risk for.

Join for free or sign in to see the full answer

Mednet Member
Radiation Oncology · UMass Memorial Medical Group
Answered on

There was a similar question posted on this forum recently, only in regards to the safety of venetoclax (Bcl-2 inhibitor) and concurrent RT.

As @Dr. First Last correctly mentioned, there is yet a paucity of robust data regarding the safety of these and other "novel" oral lymphoma agents when taken during radiation treatment.

Nevertheless, there is a small (80 patients) retrospective review by Ho et al., Blood 2019 which looked at the toxicity profiles associated with ibrutinib, venetoclax, and lenalidomide concurrent with radiation treatment for lymphoma, as compared to sequential therapy of novel agent followed by RT (separated by 5-day or more interval).

Based on the results from that publication, concurrent RT and ibrutinib (BTK inhibito...

Join for free or sign in to see the full answer

Mednet Member
Radiation Oncology · The Oregon Clinic-Radiation Oncology West
Answered on

When in doubt, due to no or very limited data on concurrent radiotherapy with new drugs, I generally err towards a break from the drug, or if not possible or feasible to take a break, counsel the patient about the uncertainties and possibility of severe side effects.

Be sure to check the elimination half-life of the drug (easy to look up on UpToDate). Some new drugs have a ~3-week elimination half-life. Waiting 3 half-lives (9 weeks) for it to clear to give a course of palliative radiotherapy may not be appropriate or feasible; starting radiotherapy sooner than that effectively means giving concurrent treatment. Other drugs, like ibrutinib in this question, have a very short 4-6 hour elimination half-life, so patients can just stop the drug...

Join for free or sign in to see the full answer

Mednet Member
Radiation Oncology · University of Vermont Medical Center
Answered on · Updated on

I have seen cutaneous bleeding in an irradiated area in an older patient who received RT for early-stage breast cancer (26 Gy in 5 fx per FAST-Forward), getting concurrent ibrutinib for CLL. She developed ecchymosis over the entire portal area without obvious trauma. It was not subtle, her entire breast was purple. We tried several challenges of taking her off ibrutinib and restarting it after her skin cleared and bleeding recurred rapidly each time, so she eventually had to stop ibrutinib. Of note, she had had cutaneous bleeding as a side effect of ibrutinib before any RT in a different area (her knee) but it was after trauma and did not recur. The bleeding was not otherwise associated with bothersome sx.

Edit: I misremembered, her counts ...

Join for free or sign in to see the full answer